Company Profile
Allogene Therapeutics Stock Price, News & Analysis
- Ticker:
- ALLO
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Allogene Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Stock performance
2.07 USD (-1.43%)
Close
Last updated: June 23, 2026 at 00:00
714.47M USD
Market cap
Why the stock is moving
ALLO is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Allogene Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Allogene Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Allogene Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Allogene Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Allogene Therapeutics Announces Planned CEO Succession
Source: Allogene Therapeutics
- 02
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Source: Allogene Therapeutics
- 03
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
Source: Allogene Therapeutics
- 04
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Source: Allogene Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Allogene Therapeutics (ALLO)?
Allogene Therapeutics (ALLO) most recently closed at 2.07 USD, a -1.43% move versus the previous session.
What is the market cap of Allogene Therapeutics (ALLO)?
Allogene Therapeutics currently has a market capitalization of 714.47M USD on BioPharmSignal.
What does Allogene Therapeutics do?
Allogene Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is ALLO stock listed?
Allogene Therapeutics (ALLO) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Allogene Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts., Biotechnology.
What is Allogene?
Allogene Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is Allogene Therapeutics targeting with Allogene?
Allogene Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is Therapeutics?
Allogene Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.